DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.

Cherifi F, Ray-Coquard I, Rubio MJ, Paoletti X, Lorusso D, Choi CH, Hasegawa K, Tan DSP, Hudson E, Davis A, Tognon G, Lheureux S, Vardar Key MA, Kurtz JE, Alexandre J, Joly F

Open source

DOI: 10.1080/14796694.2025.2496133
Published: 2025 Jun
Container: Future oncology (London, England)
Publisher: Taylor & Francis
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2496133,
  title = {DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.},
  author = {Cherifi F and Ray-Coquard I and Rubio MJ and Paoletti X and Lorusso D and Choi CH and Hasegawa K and Tan DSP and Hudson E and Davis A and Tognon G and Lheureux S and Vardar Key MA and Kurtz JE and Alexandre J and Joly F},
  year = {2025},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2025.2496133},
  url = {https://doi.org/10.1080/14796694.2025.2496133}
}

RIS

TY  - JOUR
TI  - DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.
AU  - Cherifi F
AU  - Ray-Coquard I
AU  - Rubio MJ
AU  - Paoletti X
AU  - Lorusso D
AU  - Choi CH
AU  - Hasegawa K
AU  - Tan DSP
AU  - Hudson E
AU  - Davis A
AU  - Tognon G
AU  - Lheureux S
AU  - Vardar Key MA
AU  - Kurtz JE
AU  - Alexandre J
AU  - Joly F
PY  - 2025
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2025.2496133
UR  - https://doi.org/10.1080/14796694.2025.2496133
ER  -

APA

F, C., I, R., MJ, R., X, P., D, L., CH, C., K, H., DSP, T., E, H., A, D., G, T., S, L., MA, V. K., JE, K., J, A., & F, J. (2025). DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.. Future oncology (London, England). https://doi.org/10.1080/14796694.2025.2496133

Source records

pubmed · retrieved 2026-09-27T01:36:00.198Z
europe-pmc · retrieved 2026-09-27T01:36:00.217Z
datacite · retrieved 2026-09-27T01:36:00.193Z
datacite · retrieved 2026-09-27T01:36:00.193Z
hal · retrieved 2026-09-27T01:36:00.228Z